Cargando…

Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy

Treating macaques with an anti-α4β7 antibody under the umbrella of combination antiretroviral therapy (cART) during early SIV infection can lead to viral remission, with viral loads maintained at < 50 SIV RNA copies/ml after removal of all treatment in a subset of animals. Depletion of CD8(+) lym...

Descripción completa

Detalles Bibliográficos
Autores principales: Wells, Chad R., Cao, Youfang, Durham, David P., Byrareddy, Siddappa N., Ansari, Aftab A., Ruddle, Nancy H., Townsend, Jeffrey P., Galvani, Alison P., Perelson, Alan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189501/
https://www.ncbi.nlm.nih.gov/pubmed/34106916
http://dx.doi.org/10.1371/journal.pcbi.1009031
_version_ 1783705509838192640
author Wells, Chad R.
Cao, Youfang
Durham, David P.
Byrareddy, Siddappa N.
Ansari, Aftab A.
Ruddle, Nancy H.
Townsend, Jeffrey P.
Galvani, Alison P.
Perelson, Alan S.
author_facet Wells, Chad R.
Cao, Youfang
Durham, David P.
Byrareddy, Siddappa N.
Ansari, Aftab A.
Ruddle, Nancy H.
Townsend, Jeffrey P.
Galvani, Alison P.
Perelson, Alan S.
author_sort Wells, Chad R.
collection PubMed
description Treating macaques with an anti-α4β7 antibody under the umbrella of combination antiretroviral therapy (cART) during early SIV infection can lead to viral remission, with viral loads maintained at < 50 SIV RNA copies/ml after removal of all treatment in a subset of animals. Depletion of CD8(+) lymphocytes in controllers resulted in transient recrudescence of viremia, suggesting that the combination of cART and anti-α4β7 antibody treatment led to a state where ongoing immune responses kept the virus undetectable in the absence of treatment. A previous mathematical model of HIV infection and cART incorporates immune effector cell responses and exhibits the property of two different viral load set-points. While the lower set-point could correspond to the attainment of long-term viral remission, attaining the higher set-point may be the result of viral rebound. Here we expand that model to include possible mechanisms of action of an anti-α4β7 antibody operating in these treated animals. We show that the model can fit the longitudinal viral load data from both IgG control and anti-α4β7 antibody treated macaques, suggesting explanations for the viral control associated with cART and an anti-α4β7 antibody treatment. This effective perturbation to the virus-host interaction can also explain observations in other nonhuman primate experiments in which cART and immunotherapy have led to post-treatment control or resetting of the viral load set-point. Interestingly, because the viral kinetics in the various treated animals differed—some animals exhibited large fluctuations in viral load after cART cessation—the model suggests that anti-α4β7 treatment could act by different primary mechanisms in different animals and still lead to post-treatment viral control. This outcome is nonetheless in accordance with a model with two stable viral load set-points, in which therapy can perturb the system from one set-point to a lower one through different biological mechanisms.
format Online
Article
Text
id pubmed-8189501
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-81895012021-06-10 Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy Wells, Chad R. Cao, Youfang Durham, David P. Byrareddy, Siddappa N. Ansari, Aftab A. Ruddle, Nancy H. Townsend, Jeffrey P. Galvani, Alison P. Perelson, Alan S. PLoS Comput Biol Research Article Treating macaques with an anti-α4β7 antibody under the umbrella of combination antiretroviral therapy (cART) during early SIV infection can lead to viral remission, with viral loads maintained at < 50 SIV RNA copies/ml after removal of all treatment in a subset of animals. Depletion of CD8(+) lymphocytes in controllers resulted in transient recrudescence of viremia, suggesting that the combination of cART and anti-α4β7 antibody treatment led to a state where ongoing immune responses kept the virus undetectable in the absence of treatment. A previous mathematical model of HIV infection and cART incorporates immune effector cell responses and exhibits the property of two different viral load set-points. While the lower set-point could correspond to the attainment of long-term viral remission, attaining the higher set-point may be the result of viral rebound. Here we expand that model to include possible mechanisms of action of an anti-α4β7 antibody operating in these treated animals. We show that the model can fit the longitudinal viral load data from both IgG control and anti-α4β7 antibody treated macaques, suggesting explanations for the viral control associated with cART and an anti-α4β7 antibody treatment. This effective perturbation to the virus-host interaction can also explain observations in other nonhuman primate experiments in which cART and immunotherapy have led to post-treatment control or resetting of the viral load set-point. Interestingly, because the viral kinetics in the various treated animals differed—some animals exhibited large fluctuations in viral load after cART cessation—the model suggests that anti-α4β7 treatment could act by different primary mechanisms in different animals and still lead to post-treatment viral control. This outcome is nonetheless in accordance with a model with two stable viral load set-points, in which therapy can perturb the system from one set-point to a lower one through different biological mechanisms. Public Library of Science 2021-06-09 /pmc/articles/PMC8189501/ /pubmed/34106916 http://dx.doi.org/10.1371/journal.pcbi.1009031 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Wells, Chad R.
Cao, Youfang
Durham, David P.
Byrareddy, Siddappa N.
Ansari, Aftab A.
Ruddle, Nancy H.
Townsend, Jeffrey P.
Galvani, Alison P.
Perelson, Alan S.
Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy
title Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy
title_full Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy
title_fullStr Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy
title_full_unstemmed Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy
title_short Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy
title_sort mechanistic basis of post-treatment control of siv after anti-α4β7 antibody therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189501/
https://www.ncbi.nlm.nih.gov/pubmed/34106916
http://dx.doi.org/10.1371/journal.pcbi.1009031
work_keys_str_mv AT wellschadr mechanisticbasisofposttreatmentcontrolofsivafterantia4b7antibodytherapy
AT caoyoufang mechanisticbasisofposttreatmentcontrolofsivafterantia4b7antibodytherapy
AT durhamdavidp mechanisticbasisofposttreatmentcontrolofsivafterantia4b7antibodytherapy
AT byrareddysiddappan mechanisticbasisofposttreatmentcontrolofsivafterantia4b7antibodytherapy
AT ansariaftaba mechanisticbasisofposttreatmentcontrolofsivafterantia4b7antibodytherapy
AT ruddlenancyh mechanisticbasisofposttreatmentcontrolofsivafterantia4b7antibodytherapy
AT townsendjeffreyp mechanisticbasisofposttreatmentcontrolofsivafterantia4b7antibodytherapy
AT galvanialisonp mechanisticbasisofposttreatmentcontrolofsivafterantia4b7antibodytherapy
AT perelsonalans mechanisticbasisofposttreatmentcontrolofsivafterantia4b7antibodytherapy